Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 240 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IV methylprednisolone (steroids) Clear all
Recruiting Phase 2 Interventional

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

NCT03579875
View directory record Official record
Conditions
Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita, Telomere Biology Disorders
Interventions
Total Body Irradiation (TBI) (Plan 1), Cyclophosphamide (CY) (Plan 1), Fludarabine (FLU), Methylprednisolone (MP), Donor mobilized PBSC infusion, G-CSF, Cyclophosphamide (CY) (Plan 2), Rituximab, Busulfan, Alemtuzumab, Melphalan
Drug · Device
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Treg Modulation With CD28 and IL-6 Receptor Antagonists

NCT04066114
View directory record Official record
Conditions
Living-Donor Kidney Transplant, Kidney Transplant Recipients
Interventions
lulizumab pegol, antithymocyte globulin (rabbit), methylprednisolone, tocilizumab, Prednisone, everolimus, belatacept, mycophenolate mofetil, mycophenolic acid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 7, 2026, 2:37 PM EDT
Recruiting Phase 3 Interventional

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

NCT02670707
View directory record Official record
Conditions
Langerhans Cell Histiocytosis
Interventions
Cytarabine, Vinblastine/prednisone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
11
States / cities
Palo Alto, California • San Diego, California • Minneapolis, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 7, 2026, 2:37 PM EDT
Active, not recruiting Phase 2 Interventional

Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia

NCT05303792
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Interventions
Cyclophosphamide, Vincristine, Dexamethasone, Inotuzumab Ozogamicin, Methotrexate, Cytarabine, Methylprednisolone, Rituximab, Prednisone, Mercaptopurine, Doxorubicin
Drug · Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
50 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
71
States / cities
Birmingham, Alabama • Irvine, California • Orange, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 2Phase 3 Interventional

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol

NCT04349410
View directory record Official record
Conditions
CoVid 19 Positive
Interventions
Hydroxychloroquine, Azithromycin, Hydroxychloroquine, Doxycycline, Hydroxychloroquine, Clindamycin, Hydroxychloroquine, Clindamycin, Primaquine - low dose., Hydroxychloroquine, Clindamycin, Primaquine - high dose., Remdesivir, Tocilizumab, Methylprednisolone, Interferon-Alpha2B, Losartan, Convalescent Serum
Drug
Lead sponsor
The Camelot Foundation
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 7, 2026, 2:37 PM EDT
Withdrawn Phase 2 Interventional

Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract

NCT02425813
View directory record Official record
Conditions
Acute Graft Versus Host Disease, Intestinal Graft Versus Host Disease
Interventions
Budesonide, Methylprednisolone Sodium Succinate
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Not applicable Interventional

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

NCT00068523
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, UV light therapy, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 7, 2026, 2:37 PM EDT
Recruiting Phase 4 Interventional

Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis

NCT07258771
View directory record Official record
Conditions
Ulcerative Colitis Acute
Interventions
Oral Upadacitinib, Intravenous Methylprednisolone, Oral Upadacitinib Placebo, Oral prednisolone Taper, Oral Prednisone - Hospital Dose Steroids
Drug
Lead sponsor
Berinstein, Jeffrey
Other
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Results available

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

NCT03792256
View directory record Official record
Conditions
Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma, T-cell Leukemia, Recurrent Disease, Acute Leukemia
Interventions
Palbociclib, Cytarabine, Methotrexate, Hydrocortisone, Doxorubicin, Prednisolone, Vincristine, Pegaspargase, Prednisone
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 31 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Loma Linda, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 7, 2026, 2:37 PM EDT
Terminated Not applicable Interventional Results available

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

NCT00608517
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate, methylprednisolone, total-body irradiation
Biological · Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Up to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
4
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

NCT01086540
View directory record Official record
Conditions
Systemic Sclerosis-Associated PAH
Interventions
Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen
Biological · Other · Diagnostic Test + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
17
States / cities
Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 7, 2026, 2:37 PM EDT
Recruiting Phase 2 Interventional

Corticosteroids for Post-Extubation Dysphagia

NCT06670521
View directory record Official record
Conditions
Dysphagia, Laryngeal Edema
Interventions
Methylprednisolone, Normal Saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Rituximab for Graves' Ophthalmopathy

NCT00595335
View directory record Official record
Conditions
Thyroid-associated Ophthalmopathy
Interventions
Rituximab, Saline, Methylprednisolone
Drug
Lead sponsor
Rebecca Bahn
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Treatment Interruption of Natalizumab

NCT01071083
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

NCT00519285
View directory record Official record
Conditions
Prostatic Neoplasms, Neoplasm Metastasis
Interventions
Aflibercept, Placebo (for aflibercept), Docetaxel, Prednisone or Prednisolone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 22, 2016 · Synced Oct 7, 2026, 2:37 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

NCT02205762
View directory record Official record
Conditions
Langerhans Cell Histiocytosis
Interventions
Prednisone, Vinblastine, mercaptopurine, INDOMETHACIN, Methotrexate, Cytosine Arabinoside, 2-chlorodeoxyadenosine, hematopoietic stem cell transplantation (RIC-HSCT), Intravenous immunoglobulin
Drug · Procedure · Biological
Lead sponsor
North American Consortium for Histiocytosis
Other
Eligibility
Up to 18 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 7, 2026, 2:37 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

NCT04884035
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
CC-220, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, CC-99282, Polatuzumab vedotin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02596971
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
Interventions
Atezolizumab, Bendamustine, Cyclophosphamide, Doxorubicin, Obinutuzumab, Prednisone, Vincristine, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
9
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 7, 2026, 2:37 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

NCT00808210
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Infliximab, Methotrexate, Methylprednisolone, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 7, 2026, 2:37 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

NCT03117751
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
Interventions
Prednisone, Vincristine, Daunorubicin, Pegaspargase, Erwinase®, Cyclophosphamide, Cytarabine, Mercaptopurine, Dasatinib, Methotrexate, Blinatumomab, Ruxolitinib, Bortezomib, Dexamethasone, Doxorubicin, Etoposide, Clofarabine, Vorinostat, Idarubicin, Nelarabine, Thioguanine, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Calaspargase Pegol
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 7, 2026, 2:37 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

NCT01287741
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Randomized Trial for Mixed Acute Rejection

NCT00771875
View directory record Official record
Conditions
Graft Rejection
Interventions
Rabbit Antithymocyte Globulin (RATG), Rituximab, Bortezomib, Acetaminophen, Antihistamine, Methylprednisolone
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Not applicable Interventional Results available

Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery

NCT01559675
View directory record Official record
Conditions
Orthostatic Hypotension, Hemodynamic Instability, Fever, Hypothermia
Interventions
Hydrocortisone High Dose, Hydrocortisone Low Dose
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 7, 2026, 2:37 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

NCT03914625
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
Interventions
Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Mercaptopurine Oral Suspension, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
365 Days to 31 Years
Enrollment
6,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
201
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 7, 2026, 2:37 PM EDT